KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Depreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E Adjustments
Ratios

TherapeuticsMD (TXMD) Amortization - Deferred Charges: 2020-2022

Historic Amortization - Deferred Charges for TherapeuticsMD (TXMD) over the last 3 years, with Sep 2022 value amounting to $2.6 million.

  • TherapeuticsMD's Amortization - Deferred Charges rose 74.81% to $2.6 million in Q3 2022 from the same period last year, while for Sep 2022 it was $21.1 million, marking a year-over-year increase of 317.92%. This contributed to the annual value of $5.7 million for FY2021, which is 124.68% up from last year.
  • As of Q3 2022, TherapeuticsMD's Amortization - Deferred Charges stood at $2.6 million, which was down 67.41% from $7.9 million recorded in Q2 2022.
  • In the past 5 years, TherapeuticsMD's Amortization - Deferred Charges registered a high of $9.0 million during Q1 2022, and its lowest value of $320,000 during Q2 2020.
  • Over the past 3 years, TherapeuticsMD's median Amortization - Deferred Charges value was $1.4 million (recorded in 2021), while the average stood at $2.7 million.
  • Data for TherapeuticsMD's Amortization - Deferred Charges shows a peak YoY soared of 611.32% (in 2022) over the last 5 years.
  • Quarterly analysis of 3 years shows TherapeuticsMD's Amortization - Deferred Charges stood at $887,000 in 2020, then surged by 72.60% to $1.5 million in 2021, then soared by 74.81% to $2.6 million in 2022.
  • Its last three reported values are $2.6 million in Q3 2022, $7.9 million for Q2 2022, and $9.0 million during Q1 2022.